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Magnetic Resonance Imaging–Guided
Phase 1 Trial of Putaminal AADC Gene
Therapy for Parkinson’s Disease
Chadwick W. Christine, MD,1 Krystof S. Bankiewicz, MD,2 Amber D. Van Laar, MD,3
R. Mark Richardson, MD,4 Bernard Ravina, MD,5a Adrian P. Kells, PhD,5b
Brendon Boot, MBBS,5c Alastair J. Martin, PhD,6 John Nutt, MD,7
Marin E. Thompson, MS,2 and Paul S. Larson, MD2
Objective: To understand the safety, putaminal coverage, and enzyme expression of adeno-associated viral vector
serotype-2 encoding the complementary DNA for the enzyme, aromatic L-amino acid decarboxylase (VY-AADC01),
delivered using novel intraoperative monitoring to optimize delivery.
Methods: Fifteen subjects (three cohorts of 5) with moderately advanced Parkinson’s disease and medically refractory
motor fluctuations received VY-AADC01 bilaterally coadministered with gadoteridol to the putamen using
intraoperative magnetic resonance imaging (MRI) guidance to visualize the anatomic spread of the infusate and calculate
coverage. Cohort 1 received 8.3 × 1011vg/ml and ≤450 μl per putamen (total dose, ≤7.5 × 1011vg); cohort 2 received the
same concentration (8.3 × 1011vg/ml) and ≤900 μl per putamen (total dose, ≤1.5 × 1012vg); and cohort 3 received
2.6 × 1012vg/ml and ≤900 μl per putamen (total dose, ≤4.7 × 1012vg). (18)F-fluoro-L-dihydroxyphenylalanine positron
emission tomography (PET) at baseline and 6 months postprocedure assessed enzyme activity; standard assessments mea-
sured clinical outcomes.
Results: MRI-guided administration of ascending VY-AADC01 doses resulted in putaminal coverage of 21% (cohort 1),
34% (cohort 2), and 42% (cohort 3). Cohorts 1, 2, and 3 showed corresponding increases in enzyme activity assessed by
PET of 13%, 56%, and 79%, and reductions in antiparkinsonian medication of –15%, –33%, and –42%, respectively, at
6 months. At 12 months, there were dose-related improvements in clinical outcomes, including increases in patient-
reported ON-time without troublesome dyskinesia (1.6, 3.3, and 1.5 hours, respectively) and quality of life.
Interpretation: Novel intraoperative monitoring of administration facilitated targeted delivery of VY-AADC01 in this phase
1 study, which was well tolerated. Increases in enzyme expression and clinical improvements were dose dependent.
ClinicalTrials.gov Identifier: NCT01973543
ANN NEUROL 2019;85:704–714
Levodopa is the most effective pharmacological treat-ment of Parkinson’s disease (PD) motor symptoms.1
Clinical benefits of levodopa treatment decline, in part
because the enzyme, L-amino acid decarboxylase (AADC),
needed to convert levodopa to dopamine is lost with dis-
ease progressesion.2,3 Dopamine is normally synthesized
by nigrostriatal neurons projecting to the putamen and
other regions where dopamine is released and binds to its
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receptors. Dopamine synthesis requires tyrosine hydroxy-
lase to make levodopa, which is converted to dopamine by
AADC. Nigrostriatal cells degenerate as PD progresses,
and projections to the putamen are largely gone within
5 years of diagnosis,2 leaving reduced levels of AADC and
dopamine in the putamen.
As PD progresses, patients require higher doses of
levodopa and adjunctive therapies to maintain motor
function.4,5 Motor fluctuations and levodopa-associated
dyskinesias occur in up to 80% of treated PD patients6
and may start within months of initiation.1 Escalating
doses of levodopa and other dopaminergic drugs are also
associated with nonmotor side effects, including impulse
control disorders and psychosis.
Studies in nonhuman primate (NHP) and rodent
models of PD have shown that adeno-associated viral vec-
tor serotype-2 carrying the complementary DNA (cDNA)
encoding the enzyme, AADC (AAV2-AADC), directly
administered to the putamen can lead to durable AADC
expression primarily in medium spiny neurons of the
putamen that do not degenerate in PD,7 bypassing the
need for dopamine production in dying nigrostriatal neu-
rons. In the rat 6-hydroxydopamine model, AAV2-AADC
increased dopamine in microdialysate in response to levo-
dopa, showing that striatal neurons can take up levodopa
and then produce and release dopamine.8
Coadministration of a gadolinium contrast agent with
an AAV2 vector provides a magnetic resonance imaging
(MRI) marker for assessing the location and volume of
treated tissue and thus a surrogate marker of the extent of
viral transduction.9,10 Studies in 1-methyl-4-phenyl-1,
2,3,6-tetrahydropyridine (MPTP)-lesioned primates showed
that AAV2-AADC coadministered with gadolinium using
real-time MRI guidance resulted in approximately 35%
striatal volumetric coverage and was associated with an
enhanced levodopa response and reduced levodopa require-
ments for a functional motor response lasting at least
8 years.11
Two earlier clinical trials using conventional stereo-
tactic administration of AAV2-AADC in the putamen
showed that gene transfer was well tolerated and could
durably increase enzyme levels measured by positron emis-
sion tomography (PET) over 5 years.12,13 These trials used
blind stereotactic techniques and low infusion volumes
(100 μl/putamen) with limited coverage of the putamen.
This phase 1 dose escalation trial sought to increase
putaminal coverage in PD patients with medically refrac-
tory motor fluctuations using a novel intraoperative MRI-
guided administration technique to monitor and optimize
the delivery of VY-AADC01 (AAV2-hAADC) and deter-
mine the percentage coverage of the putamen.9 Unlike pre-
vious gene therapy trials, which used a fixed volume of
100 μl/putamen,12,13 we infused larger volumes of up to
900 μl/putamen to increase the percentage of VY-AADC01-
treated putamen based on subjects’ putaminal anatomy. The
primary objective was the safety of the MRI-guided adminis-
tration technique. Secondary objectives were assessed AADC
activity changes in response to levodopa, clinical outcomes
over 12 months, and the durability of those changes after
1 year.
Materials and Methods
Protocol Approval and Patient Consent
The protocol (NCT01973543; PD-1101) and subject informed
consent forms were approved by the Institutional Review Board
(IRB) at the University of California, San Francisco (UCSF), the
University of Pittsburgh, and the US Food and Drug Adminis-
tration (FDA); the protocol was also reviewed and approved by
the Recombinant DNA Advisory Committee of the National
Institutes of Health. The substudy of the effects of intravenous
levodopa was approved by the Oregon Health & Science University
(OHSU) IRB. A data safety monitoring board reviewed ongoing
safety data. All subjects provided written informed consent before
trial participation.
Study Procedure
Subjects. Key inclusion criteria included age 40 to
70 years; PD with medically refractory motor fluctuations;
modified Hoehn and Yahr Stage ≥2.5 off medication; his-
tory and screening examination showing responsiveness to
dopaminergic therapy; and optimized and stable anti-
parkinsonian medication for ≥4 weeks before screening.
Key exclusion criteria included atypical parkinsonism; pre-
vious stereotactic neurosurgery for PD; unstable psychiat-
ric disorder or other medical problem that would interfere
with the safe conduct of the study; or neutralizing anti-
body titer to AAV2 ≥ 1:1,200 (see www.clinicaltrials.gov
for full list of criteria).
Dosing. Cohort 1 received a concentration of 8.3 × 1011vg
(vector genomes)/ml and up to 450 μl per putamen for a
total dose of up to 7.5 × 1011vg; cohort 2 received the same
concentration of 8.3 × 1011vg/mL and up to 900 μl per
putamen for a total dose of up to 1.5 × 1012vg; and cohort
3 received a higher concentration of 2.6 × 1012vg/ml with
the same volume as cohort 2 of up to 900 μl per putamen
for a total dose of up to 4.7 × 1012vg.
VY-AADC01 Preparation and Administration. VY-AADC01
consists of recombinant AAV2 capsids carrying the cDNA
of the human AADC gene under the control of the cyto-
megalovirus immediate early promoter. Both vector and
excipient for dilution were manufactured in compliance
with FDA current good manufacturing practice at the
Children’s Hospital of Philadelphia. The AAV vector was
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produced by transient transfection of an adherent HEK293
cell line using three bacteria-produced plasmids and then
purified by a combination of ion exchange chromatograph
and ultracentrifugation.
On the morning of administration, subjects were
admitted to the neurosurgical service and taken to the MRI
suite. Under general anesthesia, subjects were positioned
supine in a carbon fiber head holder. Bilateral frontal burr
holes were planned, each capable of accommodating two
trajectories to the putamen (one anterior and one posterior)
that avoided visible blood vessels, ventricles, and large peri-
vascular spaces; the postcommissural motor region of the
putamen was preferentially targeted whenever anatomically
feasible. Intraoperative navigation and delivery of VY-
AADC01 used skull mounted SmartFrames with the
Clearpoint neuro-navigational system (MRI Interventions,
Inc., Irvine, CA). SmartFlow cannulae with a stepped tip
design to resist reflux (MRI Interventions, Inc.) were placed
in both putamen (usually in the posterior target first) and
simultaneous administration of VY-AADC01 admixed with
gadoteridol (1–2 mM) was performed using convection
enhanced delivery. Serial MR images (MP-RAGE [magneti-
zation-prepared rapid gradient echo]; 3-minute acquisition
time) were acquired to monitor distribution and assess tar-
get coverage (Fig 1). The cannulae were removed after
completing the initial infusions and reinserted along a sec-
ond and, in some cases, a third trajectory for additional
infusions. After administration was complete, the cannualae
and SmartFrames were removed, burr hole covers placed,
and the scalp closed. Participants were admitted for at least
1 night of observation.
Putamen Coverage Analysis
Distribution of VY-AADC01 within the putamen was analyzed
using iPlan Flow software (Brainlab AG, Munich, Germany). Puta-
men segmentation was performed on a preadministration MRI
acquisition (VPut) and gadoteridol enhancement volumetrically seg-
mented on end-of-administration T1 volume MRI acquisitions
(VGad). Volume of VY-AADC01 distribution within each putamen
(Vd) was generated by fusing the MRI images and calculating the
intersection of VGad and VPut. VY-AADC01 distribution across sub-
jects was normalized and presented as percentage putamen coverage.
18F-Dopa PET Scans
(18)F-fluoro-L-dihydroxyphenylalanine (18F-dopa) brain PET scans
were acquired before and 5 to 6 months after administration of
VY-AADC01. Carbidopa, 2.5 mg/kg (maximum dose, 200 mg),
was taken orally 60 to 90 minutes before 18F-dopa administration.
18F-dopa (3 mCi) was injected as a bolus in an antecubital vein.
Acquisition frames captured 65 to 75 minutes after 18F-dopa admin-
istration were analyzed. Data were quantified as previously
described,14 yielding the striatum (putamen) to occipital cortex stan-
dardized uptake value ratio (SOR-1) and expressed as percentage
change from baseline. The region of interest for the 18F-dopa analysis
was the whole putamen and not limited to the region of the
administration.
Clinical Assessments
Subjects were evaluated at baseline and 3, 6, 12, 24, and 36 months
post–VY-AADC01 administration; 18- and 30-month time points
were added after study start and are available for some endpoints and
subjects. Subjects completed Hauser motor diaries15 for either 2 or
3 consecutive days (after a protocol amendment to lengthen diary
duration). The Unified Parkinson’s Disease Rating Scale (UPDRS)
was measured at baseline and follow-up visits in the functionally
defined off state, 12 or more hours after the last dose of dopaminergic
FIGURE 1: Representative MP-RAGE images during simultaneous bilateral administration of VY-AADC01 in the putamen. Axial
image (left) shows gadoteridol enhancement as a surrogate marker for vector distribution with two administrations in the
posterior portion of each putamen. Coronal oblique image (right) in-plane with the right infusion cannula during vector delivery;
part of the skull mounted SmartFrame aiming device is visible above the burr hole (white arrow), as is the SmartFlow cannula
(black arrow). MP-RAGE = magnetization-prepared rapid gradient echo.
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medication(s), and in the fully on state as judged by the patient and
investigator 1 hour following the first morning dose; an additional
one-half to one carbidopa/levodopa 25/100 tablet was administered
if the subject was not fully “on” as judged by the subject and
investigator. Quality of life (QoL) was assessed using the 39-item PD
Questionnaire (PDQ-39) at baseline and every 6 months.
Changes in antiparkinsonian medications were allowed fol-
lowing the administration of VY-AADC01 in response to
increased dyskinesia or reduced need for medication based on
investigator judgement. Antiparkinsonian medications were stan-
dardized to a levodopa equivalent dose (LED).16,17
Thirteen of the 15 subjects travelled to an independent
site (OHSU) both before and approximately 6 months after
VY-AADC01 administration. On sequential days, threshold
(0.6 mg/kg/h) or suprathreshold (1.2 mg/kg/h) doses of intrave-
nous levodopa were administered for 2 hours; dosing order was
randomized and blinded. Oral carbidopa (25 mg) was administered
1 hour before, during, and 1 hour after the infusion. UPDSR-III
and other clinical and laboratory measures were assessed every
30 minutes for up to 6.5 hours as previously described.18
Statistical Analysis
Observed data and changes from baseline are reported as
mean  standard error of the mean. Analysis of motor diaries
was normalized to a 16-hour waking day. For the intravenous
levodopa substudy, area under the curve (AUC) analysis of
UPDRS-III measures were calculated.18
Results
Baseline Characteristics
Three dosing cohorts of 5 subjects each were enrolled and
received VY-AADC01. Of 17 patients screened, 1 was
excluded because of elevated anti-AAV2 antibody titer and
1 because of Hoehn and Yahr score below the inclusion cri-
terion. Demographic and baseline characteristics (Table 1)
were similar across cohorts except for the UPDRS-III on
medication, which was lower in cohort 1, and dyskinesia
(by the Unified Dyskinesia Rating Scale), which was higher
in cohort 3. Efficacy and safety data are reported through
August 8, 2018, when efficacy data for cohort 1 were avail-
able through 36 months, cohort 2 through 24 months, and
cohort 3 through 18 months.
Safety
The surgical procedure was generally well tolerated; 14 sub-
jects returned home within 2 days of surgery. One participant
experienced a deep venous thrombosis (DVT), pulmonary
TABLE 1. Demographic and Baseline Characteristics
Cohort 1
7.5 × 1011vg
(N = 5)
Cohort 2
1.5 × 1012vg
(N = 5)
Cohort 3
4.7 × 1012vg
(N = 5)
Total
(N = 15)
Age (years) 57.4 (3.2) 58.4 (3.9) 57.4 (2.0) 57.7 (1.7)
Sex 1 female
4 males
5 males 1 female
4 males
2 females
13 males
Duration of PD (years) 9.9 (2.1) 10.1 (0.7) 8.5 (1.6) 9.5 (0.9)
UPDRS-II off medication 13.6 (0.9) 16.0 (0.8) 19.8 (3.5) 16.5 (1.3)
UPDRS-II on medication 3.0 (1.3) 3.6 (0.7) 5.0 (1.7) 3.9 (0.7)
UPDRS-III off medication 37.2 (2.6) 35.8 (3.4) 38.2 (4.3) 37.1 (1.9)
UPDRS-III on medication 7.6 (2.3) 17.0 (1.7) 16.0 (1.4) 13.5 (1.5)
Hauser diary OFF-time
(normalized hours)
4.9 (0.8) 4.2 (0.6) 4.7 (0.5) 4.6 (0.4)
Hauser diary ON-time
(normalized hours)
10.5 (1.0) 10.7 (0.8) 10.3 (0.7) 10.5 (0.4)
Modified H&Y stage Stage 3: 5 Stage 3: 5 Stage 3: 3
Stage 4: 2
Stage 3: 13
Stage 4: 2
UDysRS Total Score 19.2 (6.0) 17.4 (5.6) 30.2 (3.9) 22.3 (3.2)
LED 1,467.5 (275.0) 1,635.5 (307.4) 1,476.5 (191.9) 1,526.5 (141.9)
Data are mean (standard error). Hauser diary data are normalized to a 16-hour day.
H&Y = Hoehn and Yahr; LED = levodopa equivalent dose; PD = Parkinson’s disease; UDyRS = Unified Dyskinesia Rating Scale; UPDRS = Unified
Parkinson’s Disease Rating Scale; vg = vector genomes.
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embolus, and subsequent atrial fibrillation, likely attributed to
immobility during the surgery. These serious adverse events
(SAE) resolved with anticoagulation and a brief course of an
antiarrhythmic. DVT prophylaxis with MRI-compatible
sequential compression devices was added to the surgical pro-
tocol, and no subsequent events were observed. No vector-
related SAE have been reported. The most common adverse
events (Table 2) were expected and temporary. Transient
increase in dyskinesias, which resolved with dose reductions
of PD medications and/or addition of amantadine, was
reported as an adverse event (AE) in 4 subjects.
Putamen Coverage, AADC Activity, and PD
Medications
Intraoperative MRI was used to visualize the distribution
of gadoteridol (a surrogate for VY-AADC01) to monitor
TABLE 2. Subjects Experiencing Treatment Emergent Serious Adverse Events and Adverse Events Occuring in
>1 Subject In Any Cohort by MedRA System Organ Class
Cohort 1
75 × 1011vg
(N = 5)
Cohort 2
15 × 1012vg
(N = 5)
Cohort 3
47 × 1012vg
(N = 5)
Total
(N = 15)
Any adverse event 5 5 5 15
Any serious averse event 0 1a 0 1
Gastrointestinal disorders
Constipation 1 2 0 3
Vomiting 1 1 0 2
Infections and infestations
Tooth abcess 2 0 0 2
Upper respiratory tract infection 2 0 1 3
Metabolism and nutrition disorders
Vitamin B12 deficiency 0 2 0 2
Musculoskeletal and
connective tissue disorders
Back pain 2 2 0 4
Musculoskeletal pain 3 0 1 4
Nervous system disorders
Dizziness 2 0 0 2
Dyskinesia 2 1 1 4
Headache 5 3 3 11
Hypoaesthesia 3 1 3 7
Memory impairment 2 0 0 2
Neuralgia 2 0 0 2
Psychiatric disorders
Depression 2 1 0 3
Vascular disorders
Orthostatic hypotension 2 0 0 2
aOne participant experienced a deep venous thrombosis, pulmonary embolus, and subsequent atrial fibrillation, likely attributed to immobility during
the surgery.
MedRA = Medical Dictionary for Regulatory Activities; vg = vector genomes.
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delivery (Fig 1). A third cannula placement was used in 4
subjects (two bilateral) to maximize putamen coverage. Post-
operatively, end-of-administration MR images were evalu-
ated to calculate volumetric coverage of the putamen, which
showed 20.7  1.4%, 33.5  2.4%, and 42.3  2.5%
coverage in cohorts 1, 2, and 3, respectively.
VY-AADC01 dose-related increases were observed in
18F-dopa PET SOR-1 assessment of AADC activity with
corresponding decreases in LED. At 6 months, 18F-dopa
uptake increased by 13.2  6.6%, 56.1  13.3%, and
79.3  14.7% in cohorts 1, 2, and 3, respectively (Fig 2).
Cohort-related increases in 18F-dopa signal correlated with
VY-AADC01 (gadoteridol) coverage (r = 0.84; p = 0.0002),
suggesting that anatomical coverage of the putamen corre-
lates with the observed increase in AADC activity.
Clinical Outcomes
UPDRS scores recorded in the off- and on-medication state
at 6, 12, 24, and 36 months showed dose-dependent
improvements (Fig 3). In the on-medication state at
12 months, UPDRS-III scores were improved (reduced) by
–9.6  1.6 for cohort 2 and –6.8  1.9 for cohort 3.
Cohort 1 had a baseline score of 7.6  2.3, which is close
to the floor of measurement, and showed a 1.8  2.7 point
worsening (increase) post–VY-AADC01 administration
(Fig 3A). In the practically defined off-medication state,
improvement in UPDRS-III was noted for all cohorts,
with mean reductions of –16.4  4.2, –17.0  3.0, and
–12.0  2.4 in cohorts 1, 2, and 3, respectively (Fig. 3B).
In cohort 1, which had the longest follow-up, this improve-
ment was sustained through 36 months.
In order to measure the time couse of response to
standardized levodopa treatments, the UPDRS-III was per-
formed at fixed 30-minute intervals before and after an
intravenous infusion of “threshold” and “superathreshold”
doses of levodopa at an independent site before and
6 months after VY-AADC01 administration (Fig 4). Across
cohorts, the AUC for UPDRS-III in response to intrave-
nous levodopa showed increases of 168% (threshold levo-
dopa dose) and 67% (suprathreshold levodopa dose) from
pre- to 6-months post-VY-AADC01 administration.
Patient reported diary data also showed dose-related
outcomes. In each cohort, we observed decreases in OFF
FIGURE 2: Percentage increase from baseline in 18F-dopa
PET signal of AADC activity and corresponding reductions in
levodopa equivalent dose at 6 months. The top of the figure
shows the increase in 18F-dopa PET assessment of AADC
activity by cohort with increasing administration volume in
cohort 2 and the same volume with an increase in genome
concentration in cohort 3. The bottom of the figure shows
corresponding reductions in levodopa equivalent dosing.
LED = levodopa equivalent dose; PET = positron emission
tomography.
FIGURE 3: Mean (SE) change from baseline in UPDRS-III
assessed in the on- (A) and off-medication (B) states. Change
in UPDRS-III scores in the on- (A) and off-medication (B) states.
Mean score reductions (improvements) were observed in
cohorts 2 and 3 on medication and all three cohorts off
medication through last follow-up. Note that UPDRS data
were not collected at month 18 for cohorts 1 and 2.
UPDRS = Unified Parkinson’s Disease Rating Scale.
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time, increases in ON time without troublesome dyskinesia
(the sum of ON time without dyskinesia and ON time
with nontroublesome dyskinesia), and decreases in ON
time with troublesome dyskinesia (Fig 5). At 12 months,
cohorts 1, 2, and 3 had increases in ON time without
troublesome dyskinesia of 1.6  0.4, 3.3  0.6, and
1.5  0.5 hours, respectively. These results were stable to
improved with additional follow-up. At 36 months, cohort
1 had a 2.1  0.6 hour increase from baseline in ON time
without troublesome dyskinesia; at 24 months, cohort
2 had a 2.7  1.4 hour increase; and at 18 months, cohort
3 had a 1.7  1.1 increase.
The improvements in diary ON time occurred despite
reductions in dopaminergic treatments and mirrored the
increase in AADC activity (Fig 2). LED dose reductions
were in response to improved clinical efficacy and, in some
cases, increased dyskinesia. The cohort-dependent mean
LED reductions were –15  10%, –33%  3.4%, and
–42  7.0%, respectively, at 6 months. LED reductions
were maintained through last follow-up in cohorts 2 and
3, but not in cohort 1 (Table 3). QoL was stable or
improved across cohorts. For cohort 1, PDQ-39 scores chan-
ged minimally from baseline (–1.9  2.5 at 12 months,
−0.8  2.1 at 24 months, and –0.9  4.6 at 36 months).
FIGURE 4: Time-action curve for UPDRS-III for threshold and suprathreshold infusions of intravenous levodopa at baseline and
approximately 6 months after administration of VY-AADC01. The figure shows the UPDRS-III time-action curves following a
threshold (0.6 mg/kg/h; left side) and suprathreshold (1.2 mg/kg/h; right side) intravenous dose of levodopa by cohort (A,B:
cohort 1; C,D: cohort 2; E,F: cohort 3). Lower scores indicate improvement. Dashed lines in each figure show data before
VY-AADC01 administration and solid lines postadministration. The gray box shows the actual infusion time. Note in cohort 2 the
time-action curve for threshold (low-dose) intravenous levodopa post-VY-AADC01 administration (C) appears similar to the
suprathreshold (high-dose) intravenous levodopa pre-VY-AADC01 administration (D). AUC = area under the curve; UPDRS = Unified
Parkinson’s Disease Rating Scale.
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For cohorts 2 and 3 at 12 months, PDQ-39 scores
improved by –8.4  2.9 and –9.1  3.5, respectively,
exceeding the minimum clinically important difference of
−4.7.19 QoL was somewhat decreased at 24 months for
cohort 2 (3.9  1.9); data for cohort 3 were not collected at
18 months.
Discussion
Results from this open-label trial show that large-volume
administrations of VY-AADC01 were well tolerated. The
novel use of intraoperative MRI-guided delivery of the
vector allowed improved volumetric coverage of the puta-
men, which, in turn, was closely correlated with increases
in AADC activity, as measured by 18F-dopa PET. More-
over, there were dose-related improvements in motor fluc-
tuations, UPDRS-III scores, and QoL measures, despite
reductions in dopaminergic medications.
AAV2 vectors have now been used with direct intracra-
nial delivery in over 150 people with PD,20 with no vector-
related serious adverse events reported to date. The most
common vector-related AE in the current trial was transient
dyskinesia. Increased dyskinesia generally occurred around
1 month after surgery, when expression of putaminal AADC
is expected to reach a steady state, and is consistent with the
mechanism of action of this therapy. Dyskinesia responded
to reductions in antiparkinsonian medications, and diary data
showed a trend toward improvements in troublesome and
nontroublesome dyskinesia (Fig 5). There were no AEs
attributed to excessive or off-target dopaminergic stimulation
such as impulse control disorders or psychosis. Volumes of
administration up to 900 μl per putamen were well tolerated
and represent a 9-fold increase in volume compared to earlier
AADC gene therapy trials.12,13 The only perioperative SAE
TABLE 3. Change From Baseline in Levodopa Equivalent Dose (LED) by Cohort
Cohort 1
7.5 × 1011vg
(N = 5)
Cohort 2
1.5 × 1012vg
(N = 5)
Cohort 3
4.7 × 1012vg
(N = 5)
Baseline 1,467.5 (275.0) 1,635.5 (307.4) 1,476.5 (191.9)
6 Months –208.0 (151.4) –553.2 (137.0) –617.8 (115.0)
12 Months –92.5 (191.7) –627.2 (246.3) –606.0 (46.7)
18 Months –176.5 (129.9) –465.3 (246.0) –614.1 (87.3)
24 Months 45.5 (158.8) –451.9 (249.2)
36 Months 347.5 (404.0)
Data are mean (SE).
LED rose above baseline in cohort 1 at 36 months. This may have been attributed to a single subject taking a supratherapeutic dose (4,500 mg/day)
of levodopa or the lower coverage and AADC expression observed in this cohort.
vg = vector genomes.
FIGURE 5: Mean diary ON and OFF time per 16-hour waking
day. Across cohorts, good quality ON time (green bars; ON
time with no dyskinesia plus ON time with nontroublesome
dyskinesia) increased over time, and both OFF time and ON
time with troublesome dyskinesia decreased over time. NTD =
nontroublesome dyskinesia; TD = troublesome dyskinesia.
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was a thromboembolic event likely related to immobility dur-
ing surgery.
In contrast to earlier trials which used smaller volumes
and did not use real-time imaging, we achieved greater cov-
erage of the putamen, as measured by gadoteridol (a gado-
linium-based contrast agent) distribution on intraoperative
MRI, which allowed monitoring and optimization of the
administration in a manner personalized to each subject’s
individual putaminal anatomy. This strategy provided a sig-
nificant advantage over traditional stereotactic techniques
used in earlier gene therapy trials,20 and allowed for modifi-
cation of administration parameters to enhance putamen
coverage based on real-time and post-hoc evaluations of
intraparenchymal distribution resulting in changes in
administration volume and technique. This is the first gene-
therapy trial reported to use such a patient-specific adminis-
tration strategy.
18F-dopa PET reflects functional AADC enzyme
activity in the medium spiny neurons and the capacity to
covert 18F-dopa to 18F-dopamine. The anatomical cover-
age of the putamen achieved during VY-AADC01 admin-
istration was highly correlated with the change in AADC
activity assessed by 18F-dopa PET (r = 0.84; p = 0.0002).
Reductions in dopaminergic medications were generally
made from 1 to 6 months after VY-AADC01 administration
in response to participant report of increased dyskinesia,
observation of increased dyskinesia by the study neurologist,
or participant reported decreased need for medication. The
marked reductions in LED in cohorts 2 and 3 did not occur
in cohort 1, nor in the two earlier AADC gene therapy
trials,20 likely because of lower volumetric coverage of the
putamen by the vector. Together with the 18F-dopa PET
data, and the findings from the intravenous levodopa sub-
study, these LED reductions suggest an increased ability to
convert levodopa to dopamine, and a reduced need for dopa-
minergic medications that is consistent with the expected
pharmacological effect of AADC gene therapy.11,21
We found that the response at 12 months measured
by UPDRS-III in the on-medication state improved by a
clinically meaningful22 –9.6 and –6.8 points in cohorts
2 and 3, respectively. Cohort 1 showed a 1.8-point wors-
ening at 12 months. This group had a low UPDRS-III on
medication at baseline (Table 1), which may have limited
the ability to detect improvement.
We assume that the administration of the AADC
gene to the putamen would increase striatal AADC enzyme
activity and therefore augment the effects of administered
levodopa, with a similar result to administering a larger dose
of levodopa. The effects of larger intravenous doses of levo-
dopa are to shorten the latency to onset and prolong the
duration of response. Larger intravenous levodopa doses do
not increase the magnitude of the clinical response; the
response is essentially all or none.23 In the intravenous levo-
dopa substudy, 6 months after AADC gene therapy, the
threshold (Fig 4, left panels) and suprathreshold (Fig 4,
right panels) infusions produced a more rapid improvement
in UPDRS-III scores. Before AADC administration, thresh-
old infusions produced no, incomplete, or brief responses
to the infusions, which, when plotted as mean responses,
showed a delayed and intermediate improvement. Thus,
there appears to be a substantial difference in the magni-
tude of effect of the levodopa infusions after AADC admin-
istration when all subjects responded fully to the threshold
infusions. This is what accounts for the apparently more
robust effect of AADC gene therapy on threshold infusions.
We also observed complementary large improvements
in off medication UPDRS-III scores that were not dose
related, as was observed in earlier AAV-AADC studies.12,13
Although it is mechanistically less clear why UPDRS-III off
medication scores would also respond to AADC gene ther-
apy, as do on medication scores, it is possible that AADC
treatment allows for improved conversion of endogenous
levodopa in remaining dopaminergic nigrostriatal axons, as
has been observed in NHPs.24 It is also possible that
AADC treatment increases the long-duration response of
levodopa, perhaps by allowing more efficient and uniform
conversion to dopamine in the putamen.1
Consistent with the improved motor function mea-
sured by UPDRS-III, patient-reported motor diary ON
and OFF time also improved over time (Fig 5). The gains
in ON time without troublesome dyskinesia stem from
reductions in both OFF time and ON time with trouble-
some dyskinesia. The ON time with nontroublesome dys-
kinesia was also reduced, which further demonstrates an
overall increase of good-quality ON time with the renewed
availability of AADC to convert levodopa to dopamine.
The pattern of response observed in the current trial may
result from increased dopamine production alone or in
combination with reduced doses of dopaminergic drugs to
offset dyskinesia. At 12 months, cohort 2 had clinically
meaningful22 increases in ON time of nearly 5 hours and
reduced troublesome dyskinesia compared to baseline.
More modest gains were noted in cohort 3, possibly attrib-
uted to the greater dyskinesia at baseline (Table 1) and
more marked reductions in dopaminergic medications.
In general, participant-reported improvement in
motor diaries showed improvements (longer ON time and
shorter OFF time) at 6 months, which increased at the
later timepoints (Fig 5). Similar findings have been noted
in MPTP-lesioned NHPs that received AADC gene trans-
fer, where there was progressive improvement in the
response to levodopa that plateaued after 12 months.25
In preclinical studies, optimal motor control after
AADC gene transfer occurred at approximately one-tenth
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the dose of intramuscular levodopa.24 In clinical practice,
however, low doses of levodopa may lead to inconsistent
absorption and variable motor control. Cohort 3 of this
trial received the highest dose of VY-AADC01 and showed
greater increases in 18F-dopa PET and larger reductions in
dopaminergic medications than cohorts 1 and 2. The aver-
age LED reduction in cohort 3 was more than 600 mg
(Table 3). The marked reductions in dopaminergic medica-
tions in cohort 3 reduced dyskinesia, but may have led to
lesser improvements in OFF time than cohort 2.
The stable to improved motor outcomes observed
over time are encouraging for the potential durability of
the treatment effect. Cohort 1 diary data showed contin-
ued improvement out to 36 months, which may reflect
underlying motor circuit plasticity in response to increased
dopamine production,6 or continued increases in AADC
expression. Earlier clinical trials with more limited vector
distribution showed stable increases in AADC activity
assessed by FMT-PET (6-[18F]Fluoro-L-m-tyrosine PET)
for up to 4 years after administration.26 NHP data have
shown stable expression for up to 15 years.27
Open-label data in PD trials must be interpreted
with caution given that randomized, blinded, placebo-
controlled trials have often failed to replicate findings from
open-label trials. Even so, there are key differences
between this and other open-label gene therapy trials in
PD. First, intraoperative MRI monitoring was used to
visualize coverage of the putamen to ensure delivery of a
dose believed to be sufficient for therapeutic efficacy based
on preclinical models. Second, there is objective imaging
evidence of dose-related increases in AADC activity.
Third, across different endpoints and independent ratings
(blinded intravenous levodopa response), there is evidence
for both dose- and time-related treatment effects that are
consistent with preclinical findings and are distinct from
placebo effects, which often peak shortly after treatment.28
Based on these open-label results, a randomized trial
using a placebo-surgery control is underway to further
understand the safety and efficacy of VY-AADC. The
recently initiated phase 2 study (NCT03562494) random-
izes subjects to either continued optimized medical man-
agement, including levodopa, or optimized medical
management plus VY-AADC. The results of this new
study will allow us to both better understand the safety
and efficacy of VY-AADC and to understand its efficacy
relative to optimal medical management alone.
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